All Stories

  1. Identification of cytochrome P450 2C18 and 2C76 in tree shrews: P450 2C18 effectively oxidizes typical human P450 2C9/2C19 chiral substrates warfarin and omeprazole with less stereoselectivity
  2. Kinetics of the inhibition of CYP3A4 and CYP2C19 activity by jabara juice and identification of the responsible inhibitory components
  3. Effects of tyrosine kinase inhibitors used for the treatment of non-small cell lung carcinoma on cytochrome P450 2J2 activities
  4. Investigation of Functional Cytochrome P450 4A Enzymes in Liver and Kidney of Pigs, Cats, Tree Shrews, and Dogs in Comparison with the Metabolic Capacity of Human P450 4A11
  5. QuinuclidineN-Oxygenation Mediated by Flavin-Containing Monooxygenases 1 and 3 in Kidney and Liver Microsomes from Humans, Monkeys, Dogs, and Pigs
  6. In Vivo and In Vitro Induction of Cytochrome P450 3A4 by Thalidomide in Humanized-Liver Mice and Experimental Human Hepatocyte HepaSH cells
  7. Rare but impaired flavin-containing monooxygenase 3 (FMO3) variants reported in a recently updated Japanese mega-databank of genome resources
  8. Transcript abundance of hepatic drug-metabolizing enzymes in two dog breeds compared with 14 species including humans
  9. Novel Tree Shrew Cytochrome P450 2Ds (CYP2D8a and CYP2D8b) Are Functional Drug-Metabolizing Enzymes that Metabolize Bufuralol and Dextromethorphan
  10. Interaction of a caffeine overdose with clinical doses of contraceptive ethinyl estradiol in a young woman
  11. Novel Cytochrome P450 2C119 Enzymes in Cynomolgus and Rhesus Macaques Metabolize Progesterone, Diclofenac, and Omeprazole
  12. Simple confirmation methods for rare but impaired variants of human flavin-containing monooxygenase 3 (FMO3) found in an updated genome resource databank
  13. Chronic Toxoplasma infection affects gene expression of drug-metabolizing enzymes in mouse liver
  14. Tree shrew cytochrome P450 2E1 is a functional enzyme that metabolises chlorzoxazone and p -nitrophenol
  15. A decreasing plasma concentration of a toxicologically active metabolite 9-carboxymethoxymethylguanine after dialysis – A potential new clinical biomarker for improving encephalopathy in patients treated with acyclovir
  16. Pharmacokinetic Models Scaled Up from Humanized Liver Mouse Data Can Account for Drug Monitoring Results of Atomoxetine and Its 4-Hydroxylated andN-Demethylated Metabolites in Pediatric Patients Genotyped for CytochromeP450 2D6
  17. Synovial fluid and plasma concentrations of tedizolid in patients with osteoarthritis infected with Staphylococcus aureus effectively determined with fluorescence detection
  18. Oxidation of Naringenin, Apigenin, and Genistein by Human Family 1 Cytochrome P450 Enzymes and Comparison of Interaction of Apigenin with Human P450 1B1.1 and Scutellaria P450 82D.1
  19. Cytochrome P450 1A2 and 2C enzymes autoinduced by omeprazole in dog hepatocytes and human HepaRG and HepaSH cells are involved in omeprazole 5-hydroxylation and sulfoxidation
  20. A family study of compound variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found by urinary phenotyping for trimethylaminuria
  21. HepaSH cells: Experimental human hepatocytes with lesser inter-individual variation and more sustainable availability than primary human hepatocytes
  22. Roles of human cytochrome P450 3A4/5 in dexamethasone 6β-hydroxylation mediated by liver microsomes and humanized liver in chimeric mice metabolically suppressed with azamulin
  23. The influence of temperature on the metabolic activity of CYP2C9, CYP2C19, and CYP3A4 genetic variants in vitro
  24. Variants of Flavin-Containing Monooxygenase 3 Found in Subjects in an Updated Database of Genome Resources
  25. High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database
  26. Liver microsomal cytochrome P450 3A-dependent drug oxidation activities in individual dogs
  27. Novel Cytochrome P450 2C94 Functionally Metabolizes Diclofenac and Omeprazole in Dogs
  28. Newly Identified Tree ShrewCytochrome P4502A13 is Expressed in Liver and Lung and Encodes a Functional Drug-Metabolizing Enzyme Similar to DogCytochrome P4502A13 and PigCytochrome P4502A19
  29. The Unique Human N10-Glucuronidated Metabolite Formation from Olanzapine in Chimeric NOG-TKm30 Mice with Humanized Livers
  30. 2-Oxidation, 3-methyl hydroxylation, and 6-hydroxylation of skatole, a contributor to the odour of boar-tainted pork meat, mediated by porcine liver microsomal cytochromes P450 1A2, 2A19, 2E1, and 3A22
  31. A comprehensive analysis of six forms of cytochrome P450 2C (CYP2C) in pigs
  32. Further survey of genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found in an updated database of genome resources and identified by phenotyping for trimethylaminuria
  33. Molecular and functional characterization of flavin-containing monooxygenases in pigs, dogs, and cats
  34. Correction to “An Updated In Silico Prediction Method for Volumes of Systemic Circulation of 323 Disparate Chemicals for Use in Physiologically Based Pharmacokinetic Models to Estimate Plasma and Tissue Concentrations after Oral Doses in Rats”
  35. Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2
  36. Newly identified tree shrew cytochrome P450 2B6 (CYP2B6) and pig CYP2B6b are functional drug-metabolising enzymes
  37. Plasma and synovial fluid concentrations of linezolid in patients with knee osteoarthritis infected with Staphylococcus aureus
  38. A Comprehensive Investigation of Dog Cytochrome P450 3A (CYP3A) Reveals a Functional Role of Newly Identified CYP3A98 in Small Intestine
  39. Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes
  40. Molecular and Functional Characterization of N-Acetyltransferases in Common Marmosets and Pigs
  41. Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies
  42. Cytochrome P450 2J Genes Are Expressed in Dogs, Cats, and Pigs, and Encode Functional Drug-Metabolizing Enzymes
  43. Cytochrome P450-dependent drug oxidation activities and their expression levels in liver microsomes of chimeric TK-NOG mice with humanized livers
  44. Probe drug T-1032 N-oxygenation mediated by cytochrome P450 3A5 in human hepatocytes in vitro and in humanized-liver mice in vivo
  45. Systematic identification and characterization of cynomolgus macaque solute carrier transporters
  46. Comparison of mouse and human cytochrome P450 mediated-drug metabolising activities in hepatic and extrahepatic microsomes
  47. Plasma Concentration Profiles for Hepatotoxic Pyrrolizidine Alkaloid Senkirkine in Humans Extrapolated from Rat Data Sets Using a Simplified Physiologically Based Pharmacokinetic Model
  48. Oxidation of 3’-methoxyflavone, 4’-methoxyflavone, and 3’,4’-dimethoxyflavone and their derivatives having 5,7-dihydroxyl moieties by human cytochromes P450 1B1 and 2A13
  49. An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals
  50. Cloning and tissue expression of ATP-binding cassette transporters in cynomolgus macaques
  51. A series of simple detection systems for genetic variants of flavin-containing monooxygenase 3 (FMO3) with impaired function in Japanese subjects
  52. Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes
  53. Pharmacokinetics of caffeine self-administered in overdose in a Japanese patient admitted to hospital
  54. Different substrate elimination rates of model drugs pH-dependently mediated by flavin-containing monooxygenases and cytochromes P450 in human liver microsomes
  55. Prediction of permeability across intestinal cell monolayers for 219 disparate chemicals using in vitro experimental coefficients in a pH gradient system and in silico analyses by trivariate linear regressions and machine learning
  56. An Updated In Silico Prediction Method for Volumes of Systemic Circulation of 323 Disparate Chemicals for Use in Physiologically Based Pharmacokinetic Models to Estimate Plasma and Tissue Concentrations after Oral Doses in Rats
  57. Pharmacokinetics of loxoprofen in a self-administered overdose in a Japanese patient admitted to hospital
  58. UDP-glucuronosyltransferase 1A4-mediated N2-glucuronidation is the major metabolic pathway of lamotrigine in chimeric NOG-TKm30 mice with humanised-livers
  59. Roles of cytochrome P450 2A6 in the oxidation of flavone, 4′-hydroxyflavone, and 4′-, 3′-, and 2′-methoxyflavones by human liver microsomes
  60. Pharmacokinetic modeling of over-the-counter drug diphenhydramine self-administered in overdoses in Japanese patients admitted to hospital
  61. Cloning, sequence analysis, and tissue expression of marmoset paraoxonase 1
  62. Feasibility of physiologically based pharmacokinetic simulations for assessing pediatric patients after accidental drug ingestion: A case study of a 1.4-year-old girl who ingested alprazolam
  63. Effects of polymorphic cytochrome P450 2A6 genotypes on chemoprevention against colorectal tumors in single Japanese cohort using daily low-dose aspirin: insights into future personalized treatments
  64. Differences in Hydrolase Activities in the Liver and Small Intestine between Marmosets and Humans
  65. Evaluation of domain of unknown function 1220 (DUF1220) for detection of human genome by quantitative polymerase chain reaction: Potential use in assessing the biodistribution of transplanted therapeutic human cells
  66. Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources
  67. Predicted Contributions of Flavin-containing Monooxygenases to the N-oxygenation of Drug Candidates Based on their Estimated Base Dissociation Constants
  68. Hepatotoxicological potential of P-toluic acid in humanised-liver mice investigated using simplified physiologically based pharmacokinetic models
  69. In vivo drug interactions of itopride and trimethylamine mediated by flavin-containing monooxygenase 3 in humanized-liver mice
  70. Methyl-hydroxylation and subsequent oxidation to produce carboxylic acid is the major metabolic pathway of tolbutamide in chimeric TK-NOG mice transplanted with human hepatocytes
  71. Pharmacokinetics of duloxetine self-administered in overdose with quetiapine and other antipsychotic drugs in a Japanese patient admitted to hospital
  72. Genetic variants of aldehyde oxidase (AOX) 1 in cynomolgus and rhesus macaques
  73. Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common marmosets genotyped for P450 2C19
  74. Different Effects of Polymorphic Flavin-Containing Monooxygenase 3 and Cytochrome P450 2A6 Activities on an Index of Arteriosclerosis as a Lifestyle-Related Disease in a General Population in Japan
  75. Different Hepatic Concentrations of Bromobenzene, 1,2-Dibromobenzene, and 1,4-Dibromobenzene in Humanized-Liver Mice Predicted Using Simplified Physiologically Based Pharmacokinetic Models as Putative Markers of Toxicological Potential
  76. Human plasma concentration-time profiles of troglitazone and troglitazone sulfate simulated by in vivo experiments with chimeric mice with humanized livers and semi-physiological pharmacokinetic modeling
  77. Trimethylamine N-oxygenation in cynomolgus macaques genotyped for flavin-containing monooxygenase 3 (FMO3)
  78. Plasma and hepatic concentrations of acetaminophen and its primary conjugates after oral administrations determined in experimental animals and humans and extrapolated by pharmacokinetic modeling
  79. Metabolic Profiles of Tetrabromobisphenol A in Humans Extrapolated from Humanized-Liver Mouse Data Using a Simplified Physiologically Based Pharmacokinetic Model
  80. Liquid chromatography-tandem mass spectrometry analysis of oxidation of 2′-, 3′-, 4′- and 6-hydroxyflavanones by human cytochrome P450 enzymes
  81. Expression of functional sulfotransferases (SULT) 1A1, 1A3, 1B1, 1C2, 1E1, and 2A1 in common marmosets
  82. Molecular cloning, sequence analysis, and tissue distribution of marmoset monoamine oxidases A and B
  83. Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital
  84. Genetic variants of UDP-glucuronosyltransferases 1A1, 1A6, and 1A9 in cynomolgus and rhesus macaques
  85. Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1
  86. Molecular characterization of UDP-glucuronosyltransferases 3A and 8A in cynomolgus macaques
  87. Novel variants in outer protein surface of flavin-containing monooxygenase 3 found in an Argentinian case with impaired capacity for trimethylamine N-oxygenation
  88. Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data
  89. Regional distributions of UDP-glucuronosyltransferase activities toward estradiol and serotonin in the liver and small intestine of cynomolgus macaques
  90. Modelled plasma concentrations of pemafibrate with co-administered typical cytochrome P450 inhibitors clopidogrel, fluconazole or clarithromycin predicted by physiologically based pharmacokinetic modelling in virtual populations
  91. Genetic variants of N-acetyltransferases 1 and 2 (NAT1 and NAT2) in cynomolgus and rhesus macaques
  92. Interleukin-1β and tumor necrosis factor-α affect cytochrome P450 expression in cynomolgus macaque hepatocytes
  93. Human Aldehyde Oxidase 1-mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes
  94. Preference forO-demethylation reactions in the oxidation of 2′-, 3′-, and 4′-methoxyflavones by human cytochrome P450 enzymes
  95. Systematic characterization of glutathione S-transferases in common marmosets
  96. Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment
  97. Metabolic profiles of coumarin in human plasma extrapolated from a rat data set with a simplified physiologically based pharmacokinetic model
  98. The marmoset cytochrome P450 superfamily: Sequence/phylogenetic analyses, genomic structure, and catalytic function
  99. Different Roles of Human Cytochrome P450 2C9 and 3A Enzymes in Diclofenac 4′- and 5-Hydroxylations Mediated by Metabolically Inactivated Human Hepatocytes in Previously Transplanted Chimeric Mice
  100. Prediction of circulating human metabolites of pemafibrate, a novel antidyslipidemic drug, using chimeric mice with humanized liver
  101. Metabolism of desloratadine by chimeric TK-NOG mice transplanted with human hepatocytes
  102. Expression levels of microRNAs that are potential cytochrome P450 regulators in cynomolgus macaques
  103. Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling
  104. Predicting successful/unsuccessful extrapolation for in vivo total clearance of model compounds with a variety of hepatic intrinsic metabolism and protein bindings in humans from pharmacokinetic data using chimeric mice with humanised liver
  105. Molecular and functional characterization of cytosolic sulfotransferases in cynomolgus macaque
  106. Functional and molecular characterization of UDP-glucuronosyltransferase 2 family in cynomolgus macaques
  107. Survey of Drug Oxidation Activities in Hepatic and Intestinal Microsomes of Individual Common Marmosets, a New Nonhuman Primate Animal Model
  108. Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes
  109. Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes
  110. Non-synonymous genetic variants of flavin-containing monooxygenase 3 (FMO3) in cynomolgus macaques
  111. Steady-State Human Pharmacokinetics of Monobutyl Phthalate Predicted by Physiologically Based Pharmacokinetic Modeling Using Single-Dose Data from Humanized-Liver Mice Orally Administered with Dibutyl Phthalate
  112. Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator‐activated receptor‐alpha modulator, in rats and monkeys
  113. Regioselective hydroxylation of an antiarrhythmic drug, propafenone, mediated by rat liver cytochrome P450 2D2 differs from that catalyzed by human P450 2D6
  114. Predictability of human pharmacokinetics of diisononyl phthalate (DINP) using chimeric mice with humanized liver
  115. Plasma and Hepatic Concentrations of Chemicals after Virtual Oral Administrations Extrapolated Using Rat Plasma Data and Simple Physiologically Based Pharmacokinetic Models
  116. Novel variants and haplotypes of human flavin-containing monooxygenase 3 gene associated with Japanese subjects suffering from trimethylaminuria
  117. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals
  118. Cytochrome P450 1A1, 2C9, 2C19, and 3A4 Polymorphisms Account for Interindividual Variability of Toxicological Drug Metabolism in Cynomolgus Macaques
  119. Molecular and Functional Characterization of N-Acetyltransferases NAT1 and NAT2 in Cynomolgus Macaque
  120. In vivo multiple metabolic pathways for a novel G protein-coupled receptor 119 agonist DS-8500a in rats: involvement of the 1,2,4-oxadiazole ring-opening reductive reaction in livers under anaerobic conditions
  121. Expression and metabolic activity of flavin-containing monooxygenase 1 in cynomolgus macaque kidney
  122. In vivo hepatic clearance of lipophilic drugs predicted by in vitro uptake data into cryopreserved hepatocytes suspended in sera of rats, guinea pigs, monkeys and humans
  123. Functionally relevant genetic variants of glutathione S-transferase GSTM5 in cynomolgus and rhesus macaques
  124. Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital
  125. Genetic Variants of Glutathione S-Transferase GSTT1 and GSTT2 in Cynomolgus Macaques: Identification of GSTT Substrates and Functionally Relevant Alleles
  126. Oxidation of flavanone and flavone by cytochrome P450 2A6
  127. Expression and inducibility of cytochrome P450s in human hepatocytes isolated from chimeric mice with humanized livers
  128. Suitable albumin concentrations for enhanced drug oxidation activities mediated by human liver microsomal cytochrome P450 2C9 and other forms predicted with unbound fractions and partition/distribution coefficients of model substrates
  129. Human urinary concentrations of monoisononyl phthalate estimated using physiologically based pharmacokinetic modeling and experimental pharmacokinetics in humanized-liver mice orally administered with diisononyl phthalate
  130. Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver
  131. Chimeric mice with humanized liver as a model for testing organophosphate and carbamate pesticide exposure
  132. Polymorphisms of cytochrome P450 2B6 (CYP2B6 ) in cynomolgus and rhesus macaques
  133. Marmoset cytochrome P450 2B6, a propofol hydroxylase expressed in liver
  134. Improved Intranasal Retentivity and Transnasal Absorption Enhancement by PEGylated Poly-l-ornithine
  135. Cytochrome P450 2A6 and Other Human P450 Enzymes in the Oxidation of Flavone and Flavanone
  136. Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies
  137. Molecular cloning and tissue distribution of a novel marmoset ABC transporter
  138. The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage
  139. Development of genotyping method for functionally relevant variants of cytochromes P450 in cynomolgus macaques
  140. Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19
  141. Marmoset pulmonary cytochrome P450 2F1 oxidizes biphenyl and 7-ethoxycoumarin and hepatic human P450 substrates
  142. Oxidation of 1-chloropyrene by human CYP1 family and CYP2A subfamily cytochrome P450 enzymes: catalytic roles of two CYP1B1 and five CYP2A13 allelic variants
  143. Efavirenz clearances in vitro and in vivo in six cynomolgus monkeys associated with polymorphic cytochrome P450 2C9 and simulated by individual physiologically based pharmacokinetic models
  144. Hepatic expression of cytochrome P450 enzymes in non-human primate species
  145. Functional characterization and tissue expression of marmoset cytochrome P450 2E1
  146. Terfenadine t-butyl hydroxylation catalyzed by human and marmoset cytochrome P450 3A and 4F enzymes in livers and small intestines
  147. Regio- and Stereo-Selective Oxidation of a Cardiovascular Drug, Metoprolol, Mediated by Cytochrome P450 2D and 3A Enzymes in Marmoset Livers
  148. Molecular Cloning and Characterization of Marmoset Aldehyde Oxidase
  149. Ratio of serum levels of AGEs to soluble RAGE is correlated with trimethylamine-N-oxide in non-diabetic subjects
  150. Marmoset Flavin-Containing Monooxygenase 3 in the Liver Is a Major Benzydamine and Sulindac Sulfide Oxygenase
  151. Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and Small-Intestine Tissues Efficiently Metabolizes Midazolam, Alprazolam, Nifedipine, and Testosterone
  152. A Case of Delayed Emergence After Propofol Anesthesia
  153. Utility of non-human primates in drug development: Comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes
  154. Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice
  155. Oxidation of R- and S-omeprazole stereoselectively mediated by liver microsomal cytochrome P450 2C19 enzymes from cynomolgus monkeys and common marmosets
  156. Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes
  157. Pre-incubation with cyclosporine A potentiates its inhibitory effects on pitavastatin uptake mediated by recombinantly expressed cynomolgus monkey hepatic organic anion transporting polypeptide
  158. Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules
  159. Roles of Human CYP2A6 and Monkey CYP2A24 and 2A26 Cytochrome P450 Enzymes in the Oxidation of 2,5,2′,5′-Tetrachlorobiphenyl
  160. In vivoindividual variations in pharmacokinetics of efavirenz in cynomolgus monkeys genotyped for cytochrome P450 2C9
  161. Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry
  162. Systematic approach to optimize a pretreatment method for ultrasensitive liquid chromatography with tandem mass spectrometry analysis of multiple target compounds in biological samples
  163. Marmoset cytochrome P450 4A11, a novel arachidonic acid and lauric acid ω-hydroxylase expressed in liver and kidney tissues
  164. Simulation of human plasma concentration–time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling
  165. Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology
  166. Identification of putative substrates for cynomolgus monkey cytochrome P450 2C8 by substrate depletion assays with 22 human P450 substrates and inhibitors
  167. Structure–Function Studies of Naphthalene, Phenanthrene, Biphenyl, and Their Derivatives in Interaction with and Oxidation by Cytochromes P450 2A13 and 2A6
  168. Analysis of gene expression for microminipig liver transcriptomes using parallel long-read technology and short-read sequencing
  169. Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population
  170. Individual Differences in Metabolic Clearance of S-Warfarin Efficiently Mediated by Polymorphic Marmoset Cytochrome P450 2C19 in Livers
  171. A New Marmoset P450 4F12 Enzyme Expressed in Small Intestines and Livers Efficiently Metabolizes Antihistaminic Drug Ebastine
  172. Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling
  173. Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model
  174. Marmoset cytochrome P450 2J2 mainly expressed in small intestines and livers effectively metabolizes human P450 2J2 probe substrates, astemizole and terfenadine
  175. Individual differences inin vitroandin vivometabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3
  176. Individual differences inin vitroandin vivometabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5
  177. Functional polymer‐dependent 3D culture accelerates the differentiation of HepaRG cells into mature hepatocytes
  178. In vitroinhibition and enhancement of liver microsomal S-777469 metabolism by long-chain fatty acids and serum albumin: insight intoin vitroandin vivodiscrepancy of metabolite formation in humans
  179. Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling
  180. Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances
  181. Analysis of six novel flavin-containing monooxygenase 3 (FMO3) gene variants found in a Japanese population suffering from trimethylaminuria
  182. Dataset for genotyping validation of cytochrome P450 2A6 whole-gene deletion ( CYP2A6 * 4 ) by real-time polymerase chain reaction platforms
  183. Molecular Cloning, Tissue Distribution, and Functional Characterization of Marmoset Cytochrome P450 1A1, 1A2, and 1B1
  184. Point mutation of cytochrome P450 2A6 (a polymorphic variant CYP2A6.25) confers new substrate specificity towards flavonoids
  185. Oxidation of pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene by human cytochrome P450 2A13
  186. Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates,S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole
  187. Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus)
  188. Human HepaRG Cells can be Cultured in Hanging-drop Plates for Cytochrome P450 Induction and Function Assays
  189. Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling
  190. Human urine and plasma concentrations of bisphenol A extrapolated from pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and semi-physiological pharmacokinetic modeling
  191. Comprehensive Evaluation for Substrate Selectivity of Cynomolgus Monkey Cytochrome P450 2C9, a New Efavirenz Oxidase
  192. Human biofluid concentrations of mono(2-ethylhexyl)phthalate extrapolated from pharmacokinetics in chimeric mice with humanized liver administered with di(2-ethylhexyl)phthalate and physiologically based pharmacokinetic modeling
  193. Slow R-warfarin 7-hydroxylation mediated by P450 2C19 genetic variants in cynomolgus monkeys in vivo
  194. Substrate Selectivities and Catalytic Activities of Marmoset Liver Cytochrome P450 2A6 Differed from Those of Human P450 2A6
  195. Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan
  196. Activation and Deactivation of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine by Cytochrome P450 Enzymes and Flavin-Containing Monooxygenases in Common Marmosets (Callithrix jacchus)
  197. Oral L-Carnitine Supplementation Increases Trimethylamine-N-oxide but Reduces Markers of Vascular Injury in Hemodialysis Patients
  198. CYP2D44 polymorphisms in cynomolgus and rhesus macaques
  199. Regioselective hydroxylation of steroid hormones by human cytochromes P450
  200. Oxidation of Acenaphthene and Acenaphthylene by Human Cytochrome P450 Enzymes
  201. Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans
  202. Genetic polymorphism of cynomolgus and rhesus macaque CYP2C9
  203. Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes
  204. Potential for drug interactions mediated by polymorphic flavin-containing monooxygenase 3 in human livers
  205. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling
  206. Zone analysis by two-dimensional electrophoresis with accelerator mass spectrometry of in vivo protein bindings of idiosyncratic hepatotoxicants troglitazone and flutamide bioactivated in chimeric mice with humanized liver
  207. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients
  208. Fluvoxamine by itself has potential to directly induce long QT syndrome at supra-therapeutic concentrations
  209. Intravenous Administration of Apomorphine Does NOT Induce Long QT Syndrome: Experimental Evidence fromIn VivoCanine Models
  210. Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam andR-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys usingin vitro–in vivocorrelation
  211. Pharmacokinetics and effects on serum cholinesterase activities of organophosphorus pesticides acephate and chlorpyrifos in chimeric mice transplanted with human hepatocytes
  212. Azithromycin Can Prolong QT Interval and Suppress Ventricular Contraction, but Will Not Induce Torsade de Pointes
  213. Evaluation of 89 Compounds for Identification of Substrates for Cynomolgus Monkey CYP2C76, a New Bupropion/Nifedipine Oxidase
  214. Human plasma concentrations of herbicidal carbamate molinate extrapolated from the pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and physiologically based pharmacokinetic modeling
  215. CYP2C19 polymorphisms account for inter-individual variability of drug metabolism in cynomolgus macaques
  216. Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine
  217. Polymorphisms of CYP2D17 in Cynomolgus and Rhesus Macaques: an Evidence of the Genetic Basis for the Variability of CYP2D-Dependent Drug Metabolism
  218. Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs
  219. Qualitative De Novo Analysis of Full Length cDNA and Quantitative Analysis of Gene Expression for Common Marmoset (Callithrix jacchus) Transcriptomes Using Parallel Long-Read Technology and Short-Read Sequencing
  220. Hepatic microsomal UDP-glucuronosyltransferase (UGT) activities in the microminipig
  221. Trimethylamine generation in patients receiving hemodialysis treated with L-carnitine
  222. Effect of Ketoconazole on the Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: An Open-Label Study in Healthy White Subjects in Germany
  223. Relationships between flavin‐containing mono‐oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population
  224. Age-related pharmacokinetic changes of acetaminophen, antipyrine, diazepam, diphenhydramine, and ofloxacin in male cynomolgus monkeys and beagle dogs
  225. Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys
  226. Evaluation of 23 Lots of Commercially Available Cryopreserved Hepatocytes for Induction Assays of Human Cytochromes P450
  227. Thalidomide Increases Human Hepatic Cytochrome P450 3A Enzymes by Direct Activation of the Pregnane X Receptor
  228. Voriconazole Metabolism, Toxicity, and the Effect of Cytochrome P450 2C19 Genotype
  229. Drug-induced Liver Toxicity Studies: Research into Human Metabolites Clarifies Their Role in Drug Development
  230. Comparison of Catalytic Properties of Cytochromes P450 3A4 and 3A5 by Molecular Docking Simulation
  231. Human Cytochrome P450 Oxidation of 5-Hydroxythalidomide and Pomalidomide, an Amino Analogue of Thalidomide
  232. The human hepatic cell line HepaRG as a possible cell source for the generation of humanized liver TK-NOG mice
  233. Systematic identification and characterization of glutathione S-transferases in cynomolgus macaque
  234. Pitavastatin as an In Vivo Probe for Studying Hepatic Organic Anion Transporting Polypeptide-Mediated Drug–Drug Interactions in Cynomolgus Monkeys
  235. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans
  236. Characterization of Microsomal Glutathione S-Transferases MGST1, MGST2, and MGST3 in Cynomolgus Macaque
  237. Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation
  238. Molecular and functional characterization of flavin-containing monooxygenases in cynomolgus macaque
  239. Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities
  240. Monkey liver cytochrome P450 2C9 is involved in caffeine 7-N-demethylation to form theophylline
  241. Plasma concentrations of melengestrol acetate in humans extrapolated from the pharmacokinetics established in in vivo experiments with rats and chimeric mice with humanized liver and physiologically based pharmacokinetic modeling
  242. Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition
  243. Metabolic Activation of Polycyclic Aromatic Hydrocarbons and Aryl and Heterocyclic Amines by Human Cytochromes P450 2A13 and 2A6
  244. In Vivo Drug Interactions of the Teratogen Thalidomide with Midazolam: Heterotropic Cooperativity of Human Cytochrome P450 in Humanized TK-NOG Mice
  245. Cardiohemodynamic and Electrophysiological Effects of Anti-influenza Drug Oseltamivir In Vivo and In Vitro
  246. Clinical Evidence of Pharmacokinetic Changes in Thalidomide Therapy
  247. Cytochrome P450 Metabolic Activities in the Small Intestine of Cynomolgus Macaques Bred in Cambodia, China, and Indonesia
  248. Drug Interactions Mediated by Drug-Metabolizing Enzymes
  249. Mechanism-based Inhibition of CYP1A1 and CYP3A4 by the Furanocoumarin Chalepensin
  250. The <i>CYP3A4</i> intron 6 C>T polymorphism (<i>CYP3A4*22</i>) is associated with reduced CYP3A4 protein level and function in human liver microsomes
  251. Monkey liver cytochrome P450 2C19 is involved in R- and S-warfarin 7-hydroxylation
  252. Variants in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population
  253. Intravenous and oral administrations of DD2 [7-Amino-2-(sulfanylmethyl)heptanoic acid] produce thrombolysis through inhibition of plasma TAFIa in rats with tissue factor-induced microthrombosis
  254. A rapid multiplex PCR assay that can reliably discriminate the cytochrome P450 2D6 whole-gene deletion allele from 2D6*10 alleles
  255. Comparison of Cytochrome P450 2C Subfamily Members in Terms of Drug Oxidation Rates and Substrate Inhibition
  256. Note to readers
  257. Cytochrome P450 2A6 Phenotyping Based on Dietary Caffeine Intake in a Japanese Population of Non-smokers
  258. In Vivo Formation of Dihydroxylated and Glutathione Conjugate Metabolites Derived from Thalidomide and 5-Hydroxythalidomide in Humanized TK-NOG Mice
  259. CYP2C76 Non-synonymous Variants in Cynomolgus and Rhesus Macaques
  260. Expression Profile of Hepatic Genes in Cynomolgus Macaques Bred in Cambodia, China, and Indonesia: Implications for Cytochrome P450 Genes
  261. Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs
  262. Different Metabolites of Human Hepatotoxic Pyrazolopyrimidine Derivative 5‐n‐Butyl‐Pyrazolo[1,5‐a]Pyrimidine Produced by Human, Rat and Monkey Cytochrome P450 1A2 and Liver Microsomes
  263. Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients
  264. Immunochemical Detection of Cytochrome P450 Enzymes in Liver Microsomes of 27 Cynomolgus Monkeys
  265. Human Liver Enzymes Responsible for Metabolic Elimination of Tyramine, a Vasopressor Agent from Daily Food
  266. Spectral Modification and Catalytic Inhibition of Human Cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by Four Chemopreventive Organoselenium Compounds
  267. Metabolism of P450 Probe Substrates by Cynomolgus Monkey CYP2C76
  268. Mechanism‐based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo
  269. Comparison of Cytochrome P450 2D6 and Variants in Terms of Drug Oxidation Rates and Substrate Inhibition
  270. Direct genotyping of Cytochrome P450 2A6 whole gene deletion from human blood samples by the SmartAmp method
  271. Two Naturally Occurring Terpenes, Dehydrocostuslactone and Costunolide, Decrease Intracellular GSH Content and Inhibit STAT3 Activation
  272. Developmental variations in metabolic capacity of flavin‐containing mono‐oxygenase 3 in childhood
  273. Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function
  274. Newly Identified CYP2C93 Is a Functional Enzyme in Rhesus Monkey, but Not in Cynomolgus Monkey
  275. In Vivo Formation of a Glutathione Conjugate Derived from Thalidomide in Humanized uPA-NOG Mice
  276. CYP1D1, pseudogenized in human, is expressed and encodes a functional drug-metabolizing enzyme in cynomolgus monkey
  277. Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1′-Hydroxylation
  278. Comparison of the Inhibitory Profiles of Itraconazole and Cimetidine in Cytochrome P450 3A4 Genetic Variants
  279. A Newly Developed DNA Microarray Is Useful to Assess Induction of Cytochromes P450 in the Cynomolgus Monkey
  280. CYP1B1 is Polymorphic in Cynomolgus and Rhesus Macaques
  281. Cynomolgus Macaque CYP4 Isoforms Are Functional,Metabolizing Arachidonic Acid
  282. Discovery of Genetic Variants in CYP1D1: Implication for Functional Integrity of CYP1D1 in Cynomolgus Macaques and Rhesus Macaques
  283. Drug Metabolism and Toxicity in Chimeric Mice with Humanized Liver
  284. Evaluation of drug toxicity with hepatocytes cultured in a micro-space cell culture system
  285. Expression of Cytochromes P450 in Fetal, Infant, and Juvenile Liver of Cynomolgus Macaques
  286. Human Cytochrome P450 1A1 Is a Novel Target Gene of Liver X Receptor α
  287. Individual Differences in Pharmacokinetics and Pharmacodynamics of Anesthetic Agent Propofol with Regard to CYP2B6 and UGT1A9 Genotype and Patient Age
  288. Microminipig, a Non-rodent Experimental Animal Optimized for Life Science Research: In Vivo Proarrhythmia Models of Drug-Induced Long QT Syndrome: Development of Chronic Atrioventricular Block Model of Microminipig
  289. Species Difference between Cynomolgus Monkeys and Humans on Cytochromes P450 2D and 3A-Dependent Drug Oxidation Activities in Liver Microsomes
  290. CYP2G2, Pseudogenized in Human, Is Expressed in Nasal Mucosa of Cynomolgus Monkey and Encodes a Functional Drug-Metabolizing Enzyme
  291. Structure−Function Relationships of Inhibition of Human Cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 Flavonoid Derivatives
  292. Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling
  293. Methodologies for Investigating Drug Metabolism at the Early Drug Discovery Stage: Prediction of Hepatic Drug Clearance and P450 Contribution
  294. Human Blood Concentrations of Cotinine, a Biomonitoring Marker for Tobacco Smoke, Extrapolated from Nicotine Metabolism in Rats and Humans and Physiologically Based Pharmacokinetic Modeling
  295. A novel CYP2A26 identified in cynomolgus monkey liver metabolizes coumarin
  296. Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population
  297. Biomonitoring of Urinary Cotinine Concentrations Associated with Plasma Levels of Nicotine Metabolites after Daily Cigarette Smoking in a Male Japanese Population
  298. Alprazolam as an In Vivo Probe for Studying Induction of CYP3A in Cynomolgus Monkeys
  299. Cynomolgus Monkey CYP2D44 Newly Identified in Liver, Metabolizes Bufuralol, and Dextromethorphan
  300. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles
  301. Human Liver Microsomal Cytochrome P450 3A Enzymes Involved in Thalidomide 5-Hydroxylation and Formation of a Glutathione Conjugate
  302. Comparison of Cytochrome P450 3A Enzymes in Cynomolgus Monkeys and Humans
  303. Comparison of the Contributions of Cytochromes P450 3A4 and 3A5 in Drug Oxidation Rates and Substrate Inhibition
  304. Identification and Characterization of CYP2C18 in the Cynomolgus Macaque (Macaca fascicularis)
  305. Effects of Histidine-Tag on Recombinant Human Cytochrome P450 3A5 Catalytic Activity in Reconstitution Systems
  306. Cloning, Expression, and Characterization of CYP3A43 in Cynomolgus Macaque (Macaca fascicularis)
  307. Approach for in Vivo Protein Binding of 5-n-Butyl-pyrazolo[1,5-a]pyrimidine Bioactivated in Chimeric Mice with Humanized Liver by Two-Dimensional Electrophoresis with Accelerator Mass Spectrometry
  308. Genetic Variants ofCYP3A4andCYP3A5in Cynomolgus and Rhesus Macaques
  309. Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes
  310. Oxidation of Endobiotics Mediated by Xenobiotic-Metabolizing Forms of Human Cytochrome P450
  311. Reverse Type I Binding Spectra of Human Cytochrome P450 1B1 Induced by Flavonoid, Stilbene, Pyrene, Naphthalene, Phenanthrene, and Biphenyl Derivatives That Inhibit Catalytic Activity: A Structure−Function Relationship Study
  312. Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding
  313. Two Novel CYP2D6*10 Haplotypes As Possible Causes of a Poor Metabolic Phenotype in Japanese
  314. Human Cytochrome P450 1A2 Involvement in the Formation of Reactive Metabolites from a Species-Specific Hepatotoxic Pyrazolopyrimidine Derivative, 5-n-Butyl-7-(3,4,5-trimethoxybenzoylamino)pyrazolo[1,5-a]pyrimidine
  315. Bonitos with Low Content of Malodorous Trimethylamine as Palliative Care for Self-reported Japanese Trimethylaminuria Subjects
  316. Cytochrome P450-depedent Drug Oxidation Activity of Liver Microsomes from Microminipigs, A Possible New Animal Model for Humans in Non-clinical Studies
  317. Dose-dependent Effects of Cigarette Smoke on Blood Biomarkers in Healthy Japanese Volunteers: Observations from Smoking and Non-smoking
  318. Genetic Polymorphisms of Glycine N-acyltransferase in Japanese Individuals
  319. Identification and Characterization of CYP2B6 cDNA in Cynomolgus Macaques (Macaca fascicularis)
  320. Inter-individual Variation in Flavin-containing Monooxygenase 3 in Livers from Japanese: Correlation with Hepatic Transcription Factors
  321. Pharmacokinetic Investigation of Increased Efficacy Against Malignant Gliomas of Carboplatin Combined With Hyperbaric Oxygenation
  322. Increased distribution of carboplatin, an anti-cancer agent, to rat brains with the aid of hyperbaric oxygenation
  323. Drug Interactions of Thalidomide with Midazolam and Cyclosporine A: Heterotropic Cooperativity of Human Cytochrome P450 3A5
  324. Interaction of Polycyclic Aromatic Hydrocarbons with Human Cytochrome P450 1B1 in Inhibiting Catalytic Activity
  325. Increased transendothelial permeability of anti-cancer agent carboplatin with the aid of hyperbaric oxygenation
  326. Effects of Enzyme Sources on Midazolam 1-Hydroxylation Activity Catalyzed by Recombinant Cytochrome P450 3A4 in Combination with NADPH-Cytochrome P450 Reductase
  327. Heterotropic Cooperativity in Oxidation Mediated by Cytochrome P450
  328. Human Cytochrome P450 2A13 Efficiently Metabolizes Chemicals in Air Pollutants: Naphthalene, Styrene, and Toluene
  329. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
  330. Comparison of Kinetic Parameters for Drug Oxidation Rates and Substrate Inhibition Potential Mediated by Cytochrome P450 3A4 and 3A5
  331. Complex Mechanism Underlying Transcriptional Control of the Haplotyped Flavin-containing Monooxygenase 3 (FMO3) Gene in Japanese: Different Regulation between Mutations in 5′-Upstream Distal Region and Common Element in Proximal Region
  332. Individual Differences in Toxicological Response Caused by a Diversity of Chemicals: Observations in Japan
  333. Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3)
  334. Involvement of human cytochrome P450 2B6 in theω- and 4-hydroxylation of the anesthetic agent propofol
  335. Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes
  336. Genetic Polymorphism of the Flavin-Containing Monooxygenase 3 (FMO3) Associated with Trimethylaminuria (Fish Odor Syndrome): Observations from Japanese Patients
  337. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes
  338. Pharmacokinetics of Antifungal Agent Micafungin in Critically Ill Patients Receiving Continuous Hemodialysis Filtration
  339. Different Mechanisms for Inhibition of Human Cytochromes P450 1A1, 1A2, and 1B1 by Polycyclic Aromatic Inhibitors
  340. Transient trimethylaminuria related to menstruation
  341. Effects of Propofol Analogs on Glucuronidation of Propofol, an Anesthetic Drug, by Human Liver Microsomes
  342. Genetic Polymorphism of Bile acid CoA: Amino acid N-acyltransferase in Japanese Individuals
  343. Missense and Nonsense Mutations of the Flavin-containing Monooxygenase 3 Gene in a Japanese Cohort
  344. Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population
  345. Effect of Genetic Variants of the Human Flavin-Containing Monooxygenase 3 on N- and S-Oxygenation Activities
  346. CYP2A13 expressed in human bladder metabolically activates 4‐aminobiphenyl
  347. Rat Cytochrome P450 2C11 in Liver Microsomes Involved in Oxidation of Anesthetic Agent Propofol and Deactivated by Prior Treatment with Propofol
  348. Prediction ofin vivodrug clearance fromin vitrodata. II: Potential inter-ethnic differences
  349. Species differences in hydrolase activities toward OT-7100 responsible for different bioavailability in rats, dogs, monkeys and humans
  350. Activities of Rat Cytochrome P450 3A and 2C Isoforms are Increased In Vivo by Magnesium Sulfate as Evidenced by Enhanced Oxidation of Bupivacaine and Testosterone in Liver Microsomes
  351. In vivo Evaluation of Coumarin and Nicotine as Probe Drugs to Predict the Metabolic Capacity of CYP2A6 Due to Genetic Polymorphism in Thais
  352. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations
  353. Three Novel Single Nucleotide Polymorphisms of the FMO3 Gene in a Japanese Population
  354. Mild trimethylaminuria observed in a Japanese cohort with liver damage
  355. CYP2A6 IS A PRINCIPAL ENZYME INVOLVED IN HYDROXYLATION OF 1,7-DIMETHYLXANTHINE, A MAIN CAFFEINE METABOLITE, IN HUMANS
  356. Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas
  357. Sexual behaviour and high risk human papillomavirus infections in Japanese women
  358. Mutagenic activation of betel quid-specific N-nitrosamines catalyzed by human cytochrome P450 coexpressed with NADPH-cytochrome P450 reductase in Salmonella typhimurium YG7108
  359. High prevalence of cytochrome P 450 2A6*1A alleles in a black African population of Ghana
  360. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers
  361. Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens
  362. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers
  363. Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients
  364. Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes
  365. Identification of a Novel Polymorphic Enhancer of the Human CYP3A4 Gene
  366. Effects of cytochrome b5 on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7
  367. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9)
  368. Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes
  369. A population phenotyping study of three drug‐metabolizing enzymes in Kyushu, Japan, with use of the caffeine test
  370. Genotoxic activation of benzophenone and its two metabolites by human cytochrome P450s in SOS/umu assay
  371. Hepatocyte Nuclear Factor-1α Is a Causal Factor Responsible for Interindividual Differences in the Expression of UDP-Glucuronosyltransferase 2B7 mRNA in Human Livers
  372. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur
  373. Identification of catalase in human livers as a factor that enhances phenytoin dihydroxy metabolite formation by human liver microsomes
  374. Evaluation of Approach to Predict the Contribution of Multiple Cytochrome P450s in Drug Metabolism Using Relative Activity Factor: Effects of the Differences in Expression Levels of NADPH–Cytochrome P450 Reductase and Cytochrome b5 in the Expression Sy...
  375. Roles of NADPH-P450 Reductase and Apo- and Holo-Cytochrome b5 on Xenobiotic Oxidations Catalyzed by 12 Recombinant Human Cytochrome P450s Expressed in Membranes of Escherichia coli
  376. Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females
  377. Formation of a Novel Quinone Epoxide Metabolite of Troglitazone with Cytotoxic to HepG2 Cells
  378. P450 and carcinogenesis.
  379. Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells
  380. Metabolic activation of carcinogenic 1-nitropyrene by human cytochrome P450 1B1 in Salmonella typhimurium strain expressing an O-acetyltransferase in SOS/umu assay
  381. Stimulation of Cytochrome P450 Reactions by Apo-cytochromeb 5
  382. Nicotine metabolism and CYP2A6 allele frequencies in Koreans
  383. Characterization of (??)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6
  384. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport
  385. Cooperativity ofα-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human
  386. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans
  387. Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1
  388. Characterization of liver microsomal 7-ethoxycoumarin O -deethylation and chlorzoxazone 6-hydroxylation activities in Japanese and Caucasian subjects genotyped for CYP2E1 gene
  389. A new PCR-based assay amplifies the E6–E7 genes of most mucosal human papillomaviruses (HPV)
  390. Inhibitory effects of amiodarone and its N‐deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions
  391. Phospholipase D Activity of Cytochrome P450 in Human Liver Endoplasmic Reticulum
  392. Role of human N-acetyltransferases, NAT1 or NAT2, in genotoxicity of nitroarenes and aromatic amines in Salmonella typhimurium NM6001 and NM6002
  393. Molecular Cloning of a Novel Human Collectin from Liver (CL-L1)
  394. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes
  395. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes
  396. Highly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes
  397. Selectivity of Polycyclic Inhibitors for Human Cytochrome P450s 1A1, 1A2, and 1B1
  398. Comparative Studies on the Catalytic Roles of Cytochrome P450 2C9 and Its Cys- and Leu-Variants in the Oxidation of Warfarin, Flurbiprofen, and Diclofenac by Human Liver Microsomes
  399. Activation and detoxication of aflatoxin B1
  400. Roles of Cytochromes P450 1A2 and 3A4 in the Oxidation of Estradiol and Estrone in Human Liver Microsomes
  401. Linkage between the distribution of mutations in theCYP2C18andCYP2C19genes in the Japanese and Caucasian
  402. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes
  403. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers
  404. Progesterone and Testosterone Hydroxylation by Cytochromes P450 2C19, 2C9, and 3A4 in Human Liver Microsomes
  405. Aflatoxin B1 8,9-Epoxide Hydrolysis in the Presence of Rat and Human Epoxide Hydrolase
  406. Reconstitution of Recombinant Cytochrome P450 2C10(2C9) and Comparison with Cytochrome P450 3A4 and Other Forms: Effects of Cytochrome P450–P450 and Cytochrome P450–b5Interactions
  407. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans
  408. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4???-hydroxylation activities in livers of Japanese and Caucasian populations
  409. Lack of Electron Transfer from Cytochrome b5 in Stimulation of Catalytic Activities of Cytochrome P450 3A4
  410. Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes
  411. High Rates of Substrate Hydroxylation by Human Cytochrome P450 3A4 in Reconstituted Membranous Vesicles: Influence of Membrane Charge
  412. Recombinant Human Cytochrome P450 1A2 and an N-Terminal-Truncated Form: Construction, Purification, Aggregation Properties, and Interactions with Flavodoxin, Ferredoxin, and NADPH-Cytochrome P450 Reductase
  413. 7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes
  414. A new Salmonella typhimurium NM5004 strain expressing rat glutathione S-transferase 5–5: use in detection of genotoxicity of dihaloalkanes using an SOS/umu test system
  415. Activation and Inactivation of Carcinogenic Dihaloalkanes and Other Compounds by Glutathione S-Transferase 5-5 in Salmonella typhimurium Tester Strain NM5004
  416. Roles of Cytochrome b5in the Oxidation of Testosterone and Nifedipine by Recombinant Cytochrome P450 3A4 and by Human Liver Microsomes
  417. Mutagenic Activation of 3-Methoxy-4-aminoazobenzene by Mouse Renal Cytochrome-P450 CYP4B1: Cloning and Characterization of Mouse CYP4B1
  418. Development of high sensitive umu test system: rapid detection of genotoxicity of promutagenic aromatic amines by Salmonella typhimurium strain NM2009 possessing high O-acetyltransferase activity
  419. Volume 317, Number 2 (1995), in the article "Expression of Cytochrome P450-3A5 in Escherichia-Coli: Effects of 5′ Modification, Purification, Spectral Characterization, Reconstitution Conditions, and Catalytic Activities," by Elizabeth M. J. Gillam, Zu...
  420. Expression of Cytochrome-P450-3A5 in Escherichia Coli: Effects of 5′ Modification, Purification, Spectral Characterization, Reconstitution Conditions, and Catalytic Activities
  421. Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7α- and coumarin 7-hydroxylations
  422. Fluorescencein situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9, and 2C10) at 10q24.1
  423. Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes
  424. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes
  425. Rat pulmonary microsomal cytochrome P-450 enzymes involved in the activation of procarcinogens
  426. Use of a newly developed tester strain Salmonella typhimurium NM2009 for the study of metabolic activation of carcinogenic aromatic amines by rat liver microsomal cytochrome P-450 enzymes
  427. Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescencein situ hybridization
  428. Cytochrome P-450 forms and its inducibility by PCB isomers in black-headed gulls and black-tailed gulls
  429. The evaluation of genotoxic activities of disinfectants and their metabolites by umu test
  430. Mutagenicity of N-nitrosodiethanolamine in the Salmonella/microsome test
  431. Activation of carcinogenic N-nitrosopropylamines to mutagens by lung and pancreas S9 fractions from various animal species and man
  432. Genotoxicity of carcinogenic N-nitrosopropylamine derivatives in the hepatocyte primary culture/DNA-repair test
  433. Inhibitory effect of organic solvents on the mutagenicity of N-nitrosodialkylamines in Salmonella